Funding · last 3 months
Waiting for Compass
Live medtech trackerJump to section:
Live updates powered by Compass AI
Real-time global intelligence on private companies, funding, and more insights sourced from LSI's primary research and three global summits.
Funding · last 3 months
Waiting for Compass
Funding · last 12 months
Waiting for Compass
Deals · last 3 months
Waiting for Compass
Deals · last 12 months
Waiting for Compass
Explore the full Compass AI platform to source and close your next investment, acquisition, partner or customer.
Neurology · Funding · last 3 months
Waiting for Compass
Neurology · Funding · last 12 months
Waiting for Compass
Neurology · Deals · last 3 months
Waiting for Compass
Neurology · Deals · last 12 months
Waiting for Compass
Chart preview — not live figures yet
Live Compass data is loading
See the full platform with every company, deal, investor and signal behind this tracker and beyond.
Live Compass data is loading
Live Compass data is loading
Explore every company, deal, investor and signal behind this tracker in the full platform.
Live Compass data is loading
Live Compass data is loading
See which investors are actively writing checks in your market and stage.
Chart preview — not live figures yet
Live Compass data is loading
Live Compass data is loading
Oct 18, 2026Resonant Link Medical is expanding what's possible for implantable devicesProfile of CEO Omari Bouknight
Oct 16, 2026LSI alumni achievements driving medtech and healthtech forwardMilestones from CMR Surgical, Nami Surgical and more
Oct 11, 2026Chipiron is rebuilding MRI from first principlesProfile of co-founder and CEO Evan Kervella279 M&A30 IPOsSince Q1 2023
The largest listed medtech companies, with AI summaries of the news moving each stock.
The group average rose 2.83%. Smith & Nephew led the listed moves at +5.64%, while Danaher was weakest at -1.76%.
Johnson & Johnson rose 3.81%. Headlines say J&J MedTech could sell DePuy Synthes to Apollo and that Shockwave Medical will rebrand as Johnson & Johnson MedTech, following a headline that Shockwave will claim the Johnson & Johnson name; no deal value or date is provided.
Abbott rose 1.99%. Its headlines cover JOT DX pricing trends in South Korea, Russia, and Austria; no prices or dates are stated.
Danaher fell 1.76%. Headlines report that Danaher promoted a new CEO from within and promoted Julie Sawyer Montgomery to CEO, and that it reported third-quarter 2026 results; no results figures are provided.
Intuitive Surgical rose 3.67%. Headlines cover its medical-device development pipeline, a grant for haptic feedback control of hand-actuated selector click events, and a report that its stock surged 10 amid da Vinci 5 demand, with full rollout set for 2025; no currency or additional date is given.
Medtronic rose 3.83%. Headlines discuss how Medtronic, Zimmer Biomet, and Smith & Nephew are thinking about acquisitions and spinoffs, refer to an FDA item on next-generation drug delivery, and report a grant for a surgical device with motor control based on sensor data; no grant amount or date is stated.
Stryker rose 3.19%. Headlines report US FDA premarket approval for the Neuroform Atlas stent system and say the company is still working through cyberattack after-effects, with its stock down more than 10 this week. Another headline says Dexcom added a former Stryker CFO to its board.
Neurology · Funding · last 3 months
$496M
▼ 36.3% vs. prior 3 months
Neurology · Funding · last 12 months
$3.7B
▼ 39.9% vs. prior 12 months
Neurology · Deals · last 3 months
32
▼ 14 vs. prior 3 months
Neurology · Deals · last 12 months
177
▼ 158 vs. prior 12 months
Integra LifeSciences reported third-quarter 2026 revenue of $411.2 million, up 2.3% year over year on a reported basis.
Abbott received CE Mark for its Cologuard Plus colorectal cancer screening test under the European Union’s IVDR.
Johnson & Johnson launched its Shockwave C2 Aero Fly Coronary IVL Catheter in the U.S.
The FDA approved GSK and Ionis Pharmaceuticals’ bepirovirsen for adults with chronic hepatitis B virus infection who meet specified treatment and biomarker criteria.
Abbott received CE Mark approval under the EU’s IVDR for its Cologuard Plus colorectal cancer screening test.
Danaher reported third-quarter 2026 net earnings of $1.2 billion, or $1.71 per diluted common share, up 34.5% year over year.
Felix will offer GRAIL's Galleri multi-cancer early detection test to eligible patients in Ontario through its virtual care platform in the coming weeks.
Amgen and AstraZeneca reported complete Phase III CROSSING results for Tezspire in adolescent and adult patients with uncontrolled, symptomatic eosinophilic oesophagitis.